‘Orkedia,’ a drug for secondary hyperparathyroidism, has entered its final gateway to insurance reimbursement in Korea.

According to industry sources, Kyowa Kirin Korea recently entered into pricing negotiations with the National Health Insurance Service for Orkedia (evocalcet), a new drug for secondary hyperparathyroidism that can develop in patients with chronic kidney disease on dialysis.

If the company and the authorities reach an agreement within the 60-day negotiation deadline, the drug could be launched with reimbursement in Q3 this year.

The drug passed the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee last month after